<DOC>
	<DOCNO>NCT00486317</DOCNO>
	<brief_summary>The purpose study expose patient OA calcitonin determine plasma calcitonin level administration 0.6 mg 0.8 mg oral calcitonin 200 IU nasal calcitonin . Also purpose assess effect different dose oral calcitonin ( 0.6 mg 0.8 mg oral ) 200 IU nasal calcitonin compare placebo serum CTX-I CTX-II . Finally assess tolerance profile different doses/formulations oral calcitonin compare placebo .</brief_summary>
	<brief_title>Pharmacokinetics/Pharmacodynamics Oral Salmon Calcitonin Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Medical history symptom knee osteoarthritis Any disease medication affect bone cartilage . Any clinical sign laboratory evidence disease , Investigator 's opinion would preclude participant adhere Protocol complete trial .</criteria>
	<gender>All</gender>
	<minimum_age>52 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Osteoarthritis , oral salmon calcitonin , tolerability , biomarkers</keyword>
</DOC>